Human Antithrombin III (AT3) AssayMax ELISA KitHuman Antithrombin III (AT3) AssayMax ELISA Kit
Move your mouse over image or click to enlarge

Human Antithrombin III (AT3) AssayMax ELISA Kit

This assay employs a quantitative enzyme immunoassay technique that measures the specified antigen in samples.

Cat# Size Price Qty Buy
EA3303-1 96 Well Plate £276.25

Additional Information

Property Value or Rating
Manufacturer Assaypro, LLC.
Product Type AssayMax™ ELISA Kits
Species Human
Assay Format Competitive ELISA
Product Size 96 Well Plate
Range 0.063-4 ug/ml
Plex Number 1
Storage Refer to component labels for details
Entrez Gene 462
Omim 107300
UniProt P01008
UniGene Hs.75599
Special Notes For Research Use Only, Not To Be Used For Diagnostic Purposes
References * Oberbach A et al. (2011) Combined Proteomic and Metabolomic Profiling of Serum Reveals Association of the Complement System with Obesity and Identifies Novel Markers of Body Fat Mass Changes. J Proteome Res. 10(10):4769-88 
* Saleh AAW et al. (2014) Markers of Inflammation and Thrombophilia in Psoriasis. Med. J. Cairo Univ. 82(1):127-131 
* Sehgal A et al. (2015) An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nature Medicine 21(5):492-497 
* Nair JK et al. (2017) Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc 
* Schochl H et al. (2017) Dual inhibition of thrombin and activated factor X attenuates disseminated intravascular coagulation and protects organ function in a baboon model of severe Gram-negative sepsis. Crit Care. 21(1):51 

" title="

* Oberbach A et al. (2011) Combined Proteomic and Metabolomic Profiling of Serum Reveals Association of the Complement System with Obesity and Identifies Novel Markers of Body Fat Mass Changes. J Proteome Res. 10(10):4769-88 
* Saleh AAW et al. (2014) Markers of Inflammation and Thrombophilia in Psoriasis. Med. J. Cairo Univ. 82(1):127-131 
* Sehgal A et al. (2015) An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nature Medicine 21(5):492-497 
* Nair JK et al. (2017) Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc 
* Schochl H et al. (2017) Dual inhibition of thrombin and activated factor X attenuates disseminated intravascular coagulation and protects organ function in a baboon model of severe Gram-negative sepsis. Crit Care. 21(1):51 

" target="_blank">

* Oberbach A et al. (2011) Combined Proteomic and Metabolomic Profiling of Serum Reveals Association of the Complement System with Obesity and Identifies Novel Markers of Body Fat Mass Changes. J Proteome Res. 10(10):4769-88 
* Saleh AAW et al. (2014) Markers of Inflammation and Thrombophilia in Psoriasis. Med. J. Cairo Univ. 82(1):127-131 
* Sehgal A et al. (2015) An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nature Medicine 21(5):492-497 
* Nair JK et al. (2017) Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc 
* Schochl H et al. (2017) Dual inhibition of thrombin and activated factor X attenuates disseminated intravascular coagulation and protects organ function in a baboon model of severe Gram-negative sepsis. Crit Care. 21(1):51 

Related Documents